Health Canada approves obesity drug Wegovy
2hon MSN
Few companies garner as much reliable attention as Novo Nordisk (NYSE: NVO) does these days. With a bull market coinciding ...
But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...
Wall Street Journal on MSN2d
Novo Nordisk Says White House Obesity Plan Is Step in Right DirectionThe Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and ...
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...
Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than ...
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback